Bioventus Inc. (BVS)
BVS Stock Price Chart
Explore Bioventus Inc. interactive price chart. Choose custom timeframes to analyze BVS price movements and trends.
BVS Company Profile
Discover essential business fundamentals and corporate details for Bioventus Inc. (BVS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
11 Feb 2021
Employees
930.00
Website
http://www.bioventus.comCEO
Robert Claypoole
Description
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
BVS Financial Timeline
Browse a chronological timeline of Bioventus Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.22, while revenue estimate is $155.64m.
Earnings released on 6 May 2026
EPS came in at $0.15 surpassing the estimated $0.09 by +66.67%, while revenue for the quarter reached $132.09m , beating expectations by +1.67%.
Earnings released on 5 Mar 2026
EPS came in at $0.24 surpassing the estimated $0.22 by +9.09%, while revenue for the quarter reached $157.90m , beating expectations by +1.91%.
Earnings released on 4 Nov 2025
EPS came in at $0.15 falling short of the estimated $0.22 by -30.23%, while revenue for the quarter reached $138.65m , missing expectations by -10.95%.
Earnings released on 6 Aug 2025
EPS came in at $0.21 falling short of the estimated $0.22 by -4.55%, while revenue for the quarter reached $147.66m , beating expectations by +6.40%.
Earnings released on 6 May 2025
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $123.88m , missing expectations by -15.07%.
Earnings released on 11 Mar 2025
EPS came in at $0.15 surpassing the estimated $0.08 by +87.50%, while revenue for the quarter reached $153.64m , beating expectations by +23.41%.
Earnings released on 5 Nov 2024
EPS came in at $0.06 matching the estimated $0.06, while revenue for the quarter reached $138.96m , missing expectations by -4.05%.
Earnings released on 6 Aug 2024
EPS came in at $0.19 surpassing the estimated $0.07 by +171.43%, while revenue for the quarter reached $151.22m , beating expectations by +9.90%.
Earnings released on 7 May 2024
EPS came in at $0.07 surpassing the estimated -$0.05 by +240.00%, while revenue for the quarter reached $129.46m , beating expectations by +9.36%.
Earnings released on 12 Mar 2024
EPS came in at $0.07 surpassing the estimated $0.06 by +16.67%, while revenue for the quarter reached $135.42m , beating expectations by +9.25%.
Earnings released on 7 Nov 2023
EPS came in at $0.05 falling short of the estimated $0.06 by -16.67%, while revenue for the quarter reached $120.79m , missing expectations by -2.55%.
Earnings released on 8 Aug 2023
EPS came in at $0.14 surpassing the estimated $0.03 by +366.67%, while revenue for the quarter reached $137.07m , beating expectations by +6.07%.
Earnings released on 16 May 2023
EPS came in at -$0.26 falling short of the estimated -$0.11 by -136.36%, while revenue for the quarter reached $119.06m , beating expectations by +2.13%.
Earnings released on 31 Mar 2023
EPS came in at -$0.06 falling short of the estimated $0.05 by -220.00%, while revenue for the quarter reached $125.83m , missing expectations by -5.17%.
Earnings released on 8 Nov 2022
EPS came in at $0.05 falling short of the estimated $0.13 by -61.54%, while revenue for the quarter reached $137.07m , missing expectations by -3.20%.
Earnings released on 11 Aug 2022
EPS came in at $0.10 falling short of the estimated $0.14 by -28.57%, while revenue for the quarter reached $140.33m , beating expectations by +1.44%.
Earnings released on 10 May 2022
EPS came in at $0.04 falling short of the estimated $0.05 by -16.67%, while revenue for the quarter reached $117.29m , missing expectations by -0.34%.
Earnings released on 10 Mar 2022
EPS came in at $0.26 surpassing the estimated $0.20 by +30.00%, while revenue for the quarter reached $130.41m , beating expectations by +0.14%.
Earnings released on 9 Nov 2021
EPS came in at $0.25 surpassing the estimated $0.13 by +92.31%, while revenue for the quarter reached $108.89m , beating expectations by +3.75%.
Earnings released on 10 Aug 2021
EPS came in at $0.16 surpassing the estimated $0.10 by +60.00%, while revenue for the quarter reached $109.82m , meeting expectations.
BVS Stock Performance
Access detailed BVS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
